ACR Convergence 2024

ACR Convergence 2024

ACR Convergence showcased cutting-edge and timely topics in rheumatology, as well as the prevention, diagnosis, and treatment of rheumatic diseases and related comorbid conditions. ACR Convergence offered hundreds of sessions to educate professionals in every segment of rheumatology. Clinicians, researchers, academicians, practice managers, pediatric rheumatologists, fellows in training, advance practice nurses, physician assistants, physical or occupational therapists: Whatever your role, ACR Convergence is the place to expand your knowledge and skills and pique your curiosity.

  • Provider:American College of Rheumatology
  • Activity Link: https://rheumatology.org/annual-meeting
  • Start Date: 2024-11-14 06:00:00
  • End Date: 2024-11-14 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 209.5 hours
  • MOC Credit Details: ABIM - 209.5 Point; Credit Type(s): Medical Knowledge (ABIM)
    ABP - 209.5 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
  • Commercial Support: Source: Aurinia Pharma - Amount: 50000.0 - Is Kind Support: False Source: Genentech (Any division) - Amount: 50000.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 25000.0 - Is Kind Support: False Source: Lilly (Any division) - Amount: 50000.0 - Is Kind Support: False
  • Activity Type: Other/Blended Learning
  • CME Finder Type: Other
  • Fee to Participate: Yes
  • Measured Outcome: Learner Competence, Learner Knowledge
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Pediatric Rheumatology, Rheumatology
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.